Table 3.
Genotype distributions and allele frequencies of five ACE2 gene polymorphisms in hypertensive patients and normotensive controls according to sex
| SNPs | Gender | Genotype/allele | Frequency | P * | OR; 95% CI; P# | Logistic regression analysis OR; 95% CI; P ★ | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Hyp | Con. | ||||||
| rs2074192 | Male | CT | 0 | 0 | |||
| TT | 52 | 54 | |||||
| CC | 56 | 68 | |||||
| C | 112 | 136 | 0.404 | 0.855; (0.592-1.235); 0.404 | 0.765; (0.651-1.34); 0.32 | ||
| T | 104 | 108 | 1.169; (0.810-1.689); 0.404 | 1.56; (0.754-1.701); 0.563 | |||
| Female | CT | 80 | 74 | 0.289 | 1.411; (0.908-2.193); 0.125 | 1.233; (0.867-2.33); 0.41 | |
| TT | 28 | 34 | 0.890; (0.510-1.553); 0.681 | 0.762; (0.467-1.493); 0.79 | |||
| CC | 44 | 60 | 0.733; (0.458-1.175); 0.197 | 0.601; (0.456-1.089); 0.34 | |||
| C | 88 | 194 | 0.492 | 1.150; (0.772-1.714); 0.492 | 0.97; (0.742-1.654); 0.32 | ||
| T | 56 | 142 | 0.492 | 0.869; (0.583-1.296); 0.492 | 0.67; (0.521-1.378); 0.51 | ||
| rs2106809 | Male | GG | 56 | 60 | - | ||
| GA | 0 | 0 | |||||
| AA | 52 | 62 | |||||
| A | 104 | 124 | 0.56 | 0.89; (0.62-1.29); 0.56 | 0.82; (0.56-1.31); 0.42 | ||
| G | 112 | 120 | 1.11; (0.77-1.60); 0.56 | 0.99; (0.68-1.56); 0.46 | |||
| Female | GG | 42 | 56 | 0.59 | 0.79; (0.49-1.28); 0.34 | 0.75; (0.51-1.34); 0.48 | |
| GA | 78 | 80 | 1.226; (0.79-1.91); 0.37 | 1.02; (0.76-1.34); 0.40 | |||
| AA | 28 | 32 | 0.992; (0.56-1.74); 0.97 | 0.85; (0.64-1.43); 0.52 | |||
| A | 134 | 144 | 0.49 | 1.12; (0.882-1.53); 0.49 | 0.98; (0.75-1.12); 0.34 | ||
| G | 160 | 192 | 0.87; (0.653-1.227); 0.49 | 0.71; (0.75-1.37); 0.32 | |||
| rs2285666 | Male | TT | 60 | 64 | |||
| TC | 0 | 0 | |||||
| CC | 48 | 58 | |||||
| T | 120 | 128 | 0.506 | 1.133; (0.784-1.636); 0.506 | 0.943; (0.68-1.56); 0.45 | ||
| C | 96 | 116 | 0.506 | 0.883; (0.611-1.275); 0.506 | 0.765; (0.587-1.215);0.456 | ||
| Female | TT | 42 | 32 | 0.028 | 1.623; (1.021-2.741); 0.049 | 1.534; (1.001-2.54); 0.031 | |
| TC | 78 | 80 | 1.159; (0.747-1.799); 0.509 | 1.062; (0.756-1.65); 0.601 | |||
| CC | 32 | 56 | 0.533; (0.322-0.884); 0.014 | 0.523; (0.28-0.79); 0.022 | |||
| T | 162 | 144 | 0.008 | 1.521; (1.113-2.078); 0.008 | 1.48; (1.05-2.241); 0.013 | ||
| C | 142 | 192 | 0.657; (0.481-0.898); 0.008 | 0.56; (0.399-0.79); 0.007 | |||
| rs6632677 | Male | GG | 106 | 118 | 0.687 | ||
| CG | 0 | 0 | |||||
| CC | 2 | 4 | |||||
| C | 4 | 8 | 0.338 | 0.557; (0.165-1.875); 0.338 | 0.543;(0.243-1.771); 0.433 | ||
| G | 212 | 236 | 0.338 | 1.797; (0.533-6.052); 0.338 | 1.652; (0.481-5.478); 0.432 | ||
| Females | GG | 142 | 158 | 0.320 | 0.899; (0.363-2.222); 0.817 | 0.844; (0.352-2.38); 0.727 | |
| CG | 10 | 8 | 1.408; (0.541-3.667); 0.481 | 1.34; (0.78-2.74); 0.39 | |||
| CC | 0 | 2 | 1.012; (0.995-1.029); 0.177 | 1.08; (0.877-1.432); 0.24 | |||
| C | 10 | 12 | 0.038 | 0.918; (0.391-2.157); 0.038 | 0.765; (0.45-1.891); 0.04 | ||
| G | 294 | 324 | 1.089; (0.464-2.558); 0.038 | 0.98; (0.77-2.34); 0.052 | |||
| rs714205 | Males | GC | 0 | 0 | |||
| GG | 60 | 68 | |||||
| CC | 48 | 54 | |||||
| C | 96 | 108 | 0.969 | 1.007; (0.697-1.456); 0.969 | 0.94; (0.543-1.526); 0.85 | ||
| G | 120 | 136 | 0.969 | 0.993; (0.687-1.435); 0.969 | 0.901; (0.877-1.62); 0.67 | ||
| Females | GC | 76 | 76 | 0.016 | 1.211; (0.780-1.879); 0.394 | 1.09; (0.69-1.92); 0.453 | |
| GG | 46 | 36 | 1.591; (1.020-2.638); 0.041 | 1.342; (1.001-2.59); 0.048 | |||
| CC | 30 | 56 | 0.492; (0.295-0.821); 0.006 | 0.43; (0.31-0.93); 0.008 | |||
| C | 136 | 188 | 0.005 | 0.637; (0.466-0.871); 0.005 | 0.599; (0.412-0.85); 0.007 | ||
| G | 168 | 148 | 1.569; (1.148-2.144); 0.005 | 1.499; (1.088-2.231); 0.005 | |||
Note: Females Hardy-Weinberg. P>0.05.
*
P was calculated by χ2 test contingency table with the corresponding degree of freedom.
#
No adjustment for age, BMI, glucose, TG, TC, LDL-C, e24-h salt intake, protein-creatinine ratio, waist-to-hip ratio.
★
Adjustment for age, BMI, glucose, TG, TC, LDL-C, e24-h salt intake, protein-creatinine ratio, waist-to-hip ratio.